Laboratory Findings After Urinary Tract Infection and Antimicrobial Prophylaxis in Children With Vesicoureteral Reflux

• Published in: Clinical pediatrics Vol. 59; no. 3; p. 259
• Main Authors: Nadkarni, Milan Dattaram, Mattoo, Tej K, Gravens-Mueller, Lisa, Carpenter, Myra A, Ivanova, Anastasia, Moxey-Mims, Marva, Greenfield, Saul P, Mathews, Ranjiv
• Format: Journal Article
• Language: English
• Published: United States 01.03.2020
• Subjects: SMZ-TMP prophylaxis; laboratory monitoring; vesicoureteral reflux (VUR); urinary tract infections
• ISSN: 1938-2707
• DOI: 10.1177/0009922819898185

It is a common practice to monitor blood tests in patients receiving long-term trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis for recurrent urinary tract infections. This multicenter, randomized, placebo-controlled trial enrolled 607 children aged 2 to 71 months with vesicoureteral reflux diagnosed after symptomatic urinary tract infection. Study participants received TMP-SMZ (n = 302) or placebo (n = 305) and were followed for 2 years. Serum electrolytes (n ≥ 370), creatinine (n = 310), and complete blood counts (n ≥ 206) were measured at study entry and at the 24-month study conclusion. We found no significant electrolyte, renal, or hematologic abnormalities when comparing the treatment and placebo groups. We observed changes in several laboratory parameters in both treatment and placebo groups as would normally be expected with physiologic maturation. Changes were within the normal range for age. Long-term use of TMP-SMX had no treatment effect on complete blood count, serum electrolytes, or creatinine. Our findings do not support routine monitoring of these laboratory tests in children receiving long-term TMP-SMZ prophylaxis.